A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of ELND006 in Healthy Elderly Subjects
Latest Information Update: 02 Aug 2011
At a glance
- Drugs ELND 006 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
Most Recent Events
- 02 Aug 2011 New trial record